Prestige Consumer Healthcare Inc. (NYSE:PBH) Short Interest Update

Key Points

• Short interest fell 14.6% in April to 2,299,621 shares (about 4.9% of the float) with a days-to-cover ratio of 3.5 based on average volume.
• Analysts carry a consensus "Hold" rating on PBH with an average price target of $76.50 (three Buys and four Holds reported; Jefferies cut its target to $66 earlier this year).
• Shares traded down 2.4% to $54.98 after a slight quarterly EPS and revenue miss, a VP sold 1,000 shares, and institutional investors now control the vast majority of stock holdings (about 99.95%).

Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) was the target of a significant drop in short interest in the month of April. As of April 15th, there was short interest totaling 2,299,621 shares, a drop of 14.6% from the March 31st total of 2,692,183 shares. Based on an average trading volume of 661,281 shares, the short-interest ratio is currently 3.5 days. Approximately 4.9% of the company's stock are sold short.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on PBH shares. Weiss Ratings reissued a "hold (c)" rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, April 21st. Jefferies Financial Group cut their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a "hold" rating on the stock in a research report on Friday, January 30th. Three research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $76.50.

Insider Activity at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,000 shares of the firm's stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total transaction of $65,930.00. Following the sale, the vice president directly owned 41,048 shares in the company, valued at $2,706,294.64. This trade represents a 2.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its holdings in Prestige Consumer Healthcare by 4.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,591,744 shares of the company's stock worth $161,723,000 after buying an additional 119,459 shares during the last quarter. State Street Corp increased its holdings in shares of Prestige Consumer Healthcare by 1.4% in the fourth quarter. State Street Corp now owns 1,992,497 shares of the company's stock valued at $122,917,000 after purchasing an additional 27,721 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Prestige Consumer Healthcare by 1.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company's stock valued at $98,776,000 after purchasing an additional 21,085 shares during the last quarter. Morgan Stanley increased its holdings in shares of Prestige Consumer Healthcare by 6.3% in the fourth quarter. Morgan Stanley now owns 1,202,927 shares of the company's stock valued at $74,209,000 after purchasing an additional 71,078 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Prestige Consumer Healthcare by 5.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 738,654 shares of the company's stock valued at $45,568,000 after purchasing an additional 35,126 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Stock Down 2.4%

PBH traded down $1.34 during trading on Friday, reaching $54.98. 712,623 shares of the stock were exchanged, compared to its average volume of 458,540. The stock has a market cap of $2.60 billion, a P/E ratio of 14.55, a price-to-earnings-growth ratio of 1.67 and a beta of 0.47. Prestige Consumer Healthcare has a twelve month low of $51.24 and a twelve month high of $89.37. The stock's 50 day moving average price is $61.10 and its two-hundred day moving average price is $62.06. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing analysts' consensus estimates of $1.16 by ($0.02). The firm had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.Prestige Consumer Healthcare's quarterly revenue was down 2.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.22 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Equities analysts expect that Prestige Consumer Healthcare will post 4.54 EPS for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.